Business
Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
AUSTIN, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the Company to initiate its Phase 2 “RENEW” clinical trial of LTI-03, the Company’s lead drug candidate for idiopathic pulmonary fibrosis (IP
About this update from Rein Therapeutics, Inc.
[{"type":"image","alt":"Rein Therapeutics","displaySize":"","headline":null,"caption":"Rein Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":188,"url":"https://media.zenfs.com/en/globenewswire.com/f6e817856ccb7baaad5e04eaa3b79161"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/InuSh0Vbvk8d2XV1VpnBvw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI2MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f6e817856ccb7baaad5e04eaa3b79161","width":300,"height":188}},"lazy":false},{"type":"text","content":"AUSTIN, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the Company to initiate its Phase 2 “RENEW” clinical trial of LTI-03, the Company’s lead drug candidate for idiopathic pulmonary fibrosis (IPF).","length":518,"tagName":"p"},{"type":"text","content":"IPF is a serious, progressive lung disease that affects hundreds of thousands of people worldwide. It scars the lungs, leaving patients short of breath and with limited treatment options. Median survival after diagnosis is just 3–5 years.","length":238,"tagName":"p"},{"type":"text","content":"Rein’s LTI-03 is a first-in-class therapy that is designed to directly target fibrosis while also protecting the lung’s ability to regenerate healthy tissue. If successful, it could represent a major breakthrough in how pulmonary fibrosis is treated.","length":250,"tagName":"p"},{"type":"text","content":"Brian Windsor, Chief Executive Officer of Rein Therapeutics, commented, “This MHRA approval marks an important milestone not only for Rein, but also for patients living with IPF. We are now working towards patient recruitment in the U.K., advancing LTI-03 into the next stage of development. Our approach is designed not only to slow disease progression, but also to preserve, and potentially restore, the lung cells that are critical to everyday breathing and quality of life. We believe LTI-03 has the potential to transform outcomes for patients while also creating substantial value for our shareholders.”","length":609,"tagName":"p"},{"type":"text","content":"Next ...